Active booster immunization for the prevention of tetanus, diphtheria & pertussis (whooping cough) in childn 4-6 yr & ≥10 yr. Passive protection against pertussis in early infancy following maternal immunization during pregnancy. Concomitant w/ inactivated poliomyelitis vaccine as alternative for 5th dose of tetanus, diphtheria & acellular pertussis (DTaP) vaccine in childn 4-6 yr. Tetanus prophylaxis in wound management.
IM 0.5 mL as a booster inj preferably in the deltoid muscle. Redosing can be used at 5‐10 yr interval. May be administered to pregnant women from 24-36 wk gestation to provide passive protection of infants against pertussis.
Hypersensitivity; life-threatening reaction after previous administration of the vaccine or a vaccine containing ≥1 of the same components. Encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) w/in 7 days following previous vaccination of pertussis-containing vaccine.
Hypersensitivity. Syncope. Do not administer intravascularly, intradermally, SC or into the buttocks. Not to be used for diseases caused by Bordetella pertussis, Corynebacterium diphtheriae or Clostridium tetani infections. Do not give fractional doses (<0.5 mL). Postpone vaccination in patients w/ acute or febrile disease. Not to be administered in persons w/ bleeding disorders eg, hemophilia or thrombocytopenia or those on anticoagulant therapy; progressive or unstable neurological disorders, uncontrolled epilepsy or progressive encephalopathy. Delay vaccination in immunocompromised patients until after any immunosuppressive treatment completion. Carefully consider use if Guillain-Barré syndrome occurred w/in 6 wk of receipt of prior tetanus-toxoid containing vaccine. Lactation. Not indicated for use in childn <4 yr.
Sign Out
f2101b2d-4517-42b7-9406-a73e00785f97.GIF)
